NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Other Operating Liabilities
NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Other Operating Liabilities of $14.64 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2019-11-04
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating liabilities for the quarter ending 2019-09-30 was $3.33M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating liabilities for the quarter ending 2019-06-30 was $5.95M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating liabilities for the quarter ending 2019-03-31 was $5.36M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating liabilities for the quarter ending 2018-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating liabilities for fiscal 2017 was $0.00.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating liabilities for fiscal 2016 was -$108.00K.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating liabilities for fiscal 2015 was -$39.00K.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating liabilities for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|---|
| 2019-09-30 | $3.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $9.28M derived: sum of 2 quarters · filed 2019-11-04 | $14.64M 10-Q · filed 2019-11-04 | ||
| 2019-06-30 | $5.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $11.31M 10-Q · filed 2019-07-29 | |||
| 2019-03-31 | $5.36M 10-Q · filed 2019-04-29 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$85.00K derived: sum of 2 quarters · filed 2019-11-04 | -$175.00K 10-Q · filed 2019-11-04 | ||
| 2018-06-30 | -$85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | -$175.00K 10-Q · filed 2019-07-29 | |||
| 2018-03-31 | -$90.00K 10-Q · filed 2019-04-29 | -$28.00K 10-Q · filed 2018-04-30 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-02-13 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2018-04-30 | ||||
| 2016-12-31 | -$108.00K 10-K · filed 2018-02-13 | ||||
| 2015-12-31 | -$39.00K 10-K · filed 2018-02-13 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-02-14 | ||||
| 2013-12-31 | $108.00K 10-K · filed 2016-02-11 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | $1.00K derived: sum of 2 quarters · filed 2015-02-09 | $28.00K derived: sum of 3 quarters · filed 2015-02-09 | $27.00K 10-K · filed 2015-02-09 | |
| 2012-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $28.00K derived: sum of 2 quarters · filed 2013-10-29 | $27.00K 10-Q · filed 2013-10-29 | $28.00K derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | $26.00K 10-Q · filed 2013-07-26 | $27.00K derived: sum of 3 quarters · filed 2014-02-11 | ||
| 2012-03-31 | -$1.00K 10-Q · filed 2013-05-02 | $0.00 derived: sum of 2 quarters · filed 2014-02-11 | |||
| 2011-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $24.00K 10-K · filed 2014-02-11 | |||
| 2011-09-30 | $23.00K 10-Q · filed 2012-10-31 | ||||
| 2010-12-31 | $101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $101.00K derived: sum of 2 quarters · filed 2013-02-08 | -$1.33M 10-K · filed 2013-02-08 | ||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | -$1.44M 10-Q · filed 2011-10-31 | |||
| 2010-06-30 | -$1.44M 10-Q · filed 2011-07-29 | ||||
| 2009-12-31 | -$1.70M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |